Kaleido Biosciences Inc (NASDAQ:KLDO) has been given an average recommendation of “Buy” by the six brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $17.70.
Several research analysts have recently weighed in on the stock. Chardan Capital assumed coverage on shares of Kaleido Biosciences in a research note on Tuesday, April 23rd. They set a “buy” rating and a $17.50 price objective on the stock. Zacks Investment Research lowered shares of Kaleido Biosciences from a “hold” rating to a “sell” rating in a research note on Wednesday, August 7th.
Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. purchased a new stake in Kaleido Biosciences during the 2nd quarter valued at approximately $1,061,000. Tower Research Capital LLC TRC acquired a new position in Kaleido Biosciences during the second quarter worth $56,000. BlackRock Inc. acquired a new position in shares of Kaleido Biosciences in the second quarter worth $2,835,000. Northern Trust Corp acquired a new position in shares of Kaleido Biosciences in the second quarter worth $145,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of Kaleido Biosciences in the second quarter worth $353,000. Institutional investors own 77.75% of the company’s stock.
NASDAQ:KLDO traded up $0.27 on Wednesday, hitting $8.64. 46,700 shares of the company’s stock were exchanged, compared to its average volume of 54,754. The business has a 50-day simple moving average of $8.60. Kaleido Biosciences has a 52 week low of $6.23 and a 52 week high of $19.00.
Kaleido Biosciences (NASDAQ:KLDO) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.09). As a group, research analysts expect that Kaleido Biosciences will post -2.81 EPS for the current year.
Kaleido Biosciences Company Profile
Kaleido BioSciences, Inc develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infections caused by multi-drug resistant bacteria; chronic kidney disease; atherosclerotic cardiovascular disease; and drug or disease induced diarrhea.
Featured Story: Why is Cost of Capital Important?
Receive News & Ratings for Kaleido Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kaleido Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.